CV Therapeutics, Inc.

Biopharmaceutical firm reports option grants

Published in Lab Business Week, July 17th, 2005

CV Therapeutics, Inc., (CVTX) announced that in accordance with Nasdaq marketplace rule 4350, the company issued new inducement stock options to 134 non-executive employees due to additional hiring, primarily in connection with its commercialization efforts to copromote Aceon (perindopril erbumine) tablets in the United States.

The inducement stock options cover an aggregate 269,100 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date.

The options have a 10-year term and vest over 4 years as follows:

Twenty percent of these options will...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2005-07-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry